Latest Information Update: 28 Nov 2007
At a glance
- Originator INSERM
- Class Interleukins
- Mechanism of Action Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hypersensitivity; Transplant rejection
Most Recent Events
- 10 Jan 1996 Preclinical development for Allergy in France (Unknown route)
- 06 Jan 1995 Preclinical development for Transplant rejection in France (Unknown route)